Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2012 Aug 15;18(16):4406-14. doi: 10.1158/1078-0432.CCR-12-0357. Epub 2012 Jun 25.

2.

Adjuvant chemotherapy for surgically resected non-small cell lung cancer.

Heon S, Johnson BE.

J Thorac Cardiovasc Surg. 2012 Sep;144(3):S39-42. doi: 10.1016/j.jtcvs.2012.03.039. Epub 2012 Apr 13. Review.

3.

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, Stumpfova M, Xiao Y, Weremowicz S, Butaney M, Heon S, Wilner K, Christensen JG, Eck MJ, Wong KK, Lindeman N, Gray NS, Rodig SJ, Jänne PA.

Cancer Res. 2011 Sep 15;71(18):6051-60. doi: 10.1158/0008-5472.CAN-11-1340. Epub 2011 Jul 26.

4.

Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.

Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2010 Dec 1;16(23):5873-82. doi: 10.1158/1078-0432.CCR-10-1588. Epub 2010 Oct 28.

5.

Skeletal age in idiopathic short stature: An analytical study by the TW3 method, Greulich and Pyle method.

Kim HJ, Song HR, Shyam A, Heon SS, Unnikrishnan R, Song SY.

Indian J Orthop. 2010 Jul;44(3):322-6. doi: 10.4103/0019-5413.65144.

6.

Metabotropic glutamate receptor-mediated LTD involves two interacting Ca(2+) sensors, NCS-1 and PICK1.

Jo J, Heon S, Kim MJ, Son GH, Park Y, Henley JM, Weiss JL, Sheng M, Collingridge GL, Cho K.

Neuron. 2008 Dec 26;60(6):1095-111. doi: 10.1016/j.neuron.2008.10.050.

7.

Amifostine and dexrazoxane enhance the rapid loss of bone mass and further deterioration of vertebrae architecture in female rats.

Mwale F, Ciobanu I, Demers CN, Antoniou J, Héon S, Servant N, Chalifour LE.

Calcif Tissue Int. 2005 Sep;77(3):175-9. Epub 2005 Sep 8.

PMID:
16151678
8.

Gender-dependent reductions in vertebrae length, bone mineral density and content by doxorubicin are not reduced by dexrazoxane in young rats: effect on growth plate and intervertebral discs.

Mwale F, Antoniou J, Héon S, Servant N, Wang C, Kirby GM, Demers CN, Chalifour LE.

Calcif Tissue Int. 2005 Mar;76(3):214-21. Epub 2004 Nov 18.

PMID:
15570399
9.

Dexrazoxane does not protect against doxorubicin-induced damage in young rats.

Héon S, Bernier M, Servant N, Dostanic S, Wang C, Kirby GM, Alpert L, Chalifour LE.

Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H499-506. Epub 2003 Apr 24.

Supplemental Content

Support Center